Relypsa raises $80 million for hyperkalaemia drug
This article was originally published in Scrip
Relypsa said on 15 August that it closed an $80 million series C preferred stock financing after it disclosed in a US Securities and Exchange Commission (SEC) filing on 10 August that it raised $49.7 million to begin a Phase III trial this year and a future new drug application (NDA) to the US FDA for patiromer (RLY5016), a high-capacity, non-absorbed oral potassium binder to treat hyperkalaemia in patients with diabetes, chronic kidney disease (CKD) and heart failure (scripintelligence.com, 14 August 2012).
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.